Your browser doesn't support javascript.
loading
Efficacy of ß-Lactam/ß-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-ß-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Gudiol, Carlota; Royo-Cebrecos, Cristina; Abdala, Edson; Akova, Murat; Álvarez, Rocío; Maestro-de la Calle, Guillermo; Cano, Angela; Cervera, Carlos; Clemente, Wanessa T; Martín-Dávila, Pilar; Freifeld, Alison; Gómez, Lucía; Gottlieb, Thomas; Gurguí, Mercè; Herrera, Fabián; Manzur, Adriana; Maschmeyer, Georg; Meije, Yolanda; Montejo, Miguel; Peghin, Maddalena; Rodríguez-Baño, Jesús; Ruiz-Camps, Isabel; Sukiennik, Teresa C; Tebe, Cristian; Carratalà, Jordi.
Afiliação
  • Gudiol C; Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Spain cgudiol@iconcologia.net.
  • Royo-Cebrecos C; Duran i Reynals Hospital, ICO, Barcelona, Spain.
  • Abdala E; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain.
  • Akova M; Infectious Diseases Department, Bellvitge University Hospital, IDIBELL, University of Barcelona, Spain.
  • Álvarez R; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain.
  • Maestro-de la Calle G; Instituto do Câncer do Estado de São Paulo, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
  • Cano A; Hacettepe University School of Medicine, Ankara, Turkey.
  • Cervera C; Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Infectious Diseases Research Group, Institute of Biomedicine of Seville (IBiS), University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain.
  • Clemente WT; Infectious Diseases Unit, Instituto de Investigación Hospital 12 de Octubre (i+12), 12 de Octubre University Hospital, School of Medicine, Universidad Complutense, Madrid, Spain.
  • Martín-Dávila P; Reina Sofía University Hospital-IMIBIC-UCO, Córdoba, Spain.
  • Freifeld A; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain.
  • Gómez L; University Hospital of Alberta, Alberta, Canada.
  • Gottlieb T; Digestive Transplant Service, Hospital das Clínicas, Universidade Federal Minas Gerais, Belo Horizonte, Brazil.
  • Gurguí M; Infectious Diseases Department, Ramon y Cajal Hospital, Madrid, Spain.
  • Herrera F; Internal Medicine, Infectious Diseases Section, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Manzur A; Internal Medicine, University Hospital Mútua de Terrassa, Barcelona, Spain.
  • Maschmeyer G; Department of Microbiology & Infectious Diseases, Concord Hospital, Concord, NSW, Australia.
  • Meije Y; Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau and Instituto de Investigación Biomédica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Montejo M; Infectious Diseases Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina.
  • Peghin M; Infectious Diseases, Hospital Rawson, San Juan, Argentina.
  • Rodríguez-Baño J; Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Academic Teaching Hospital of Charité University Medical School, Berlin, Germany.
  • Ruiz-Camps I; Infectious Disease Unit, Internal Medicine Department, Barcelona Hospital, SCIAS, Barcelona, Spain.
  • Sukiennik TC; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain.
  • Tebe C; Infectious Diseases Unit, Cruces University Hospital, Bilbao, Spain.
  • Carratalà J; REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain.
Antimicrob Agents Chemother ; 61(8)2017 08.
Article em En | MEDLINE | ID: mdl-28584145
ABSTRACT
ß-Lactam/ß-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-ß-lactamase (ESBL) bloodstream infection (BSI) the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bacteriemia / Enterobacteriaceae / Infecções por Enterobacteriaceae / Inibidores de beta-Lactamases / Antibacterianos / Neutropenia Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bacteriemia / Enterobacteriaceae / Infecções por Enterobacteriaceae / Inibidores de beta-Lactamases / Antibacterianos / Neutropenia Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article